Loss of KA1 expression in the progression of colorectal cancer

Cancer Research

Volumn 59, Issue 22, 1999, Pages 5724-5731

  Lombardi, Donald P ^a,b,d   Geradts, Joseph ^c   Foley, Julie F ^a   Chiao, Chia ^a   Lamb, Pattie W ^a   Barrett, J Carl ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Division of Hematology Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; GLYCOSYLATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; ADENOMA; ADULT; AGED; ANALYSIS OF VARIANCE; CANCER STAGING; CARCINOMA; CELL ADHESION; CELL CULTURE; CHEMISTRY; COLON; COLON TUMOR; DISEASE COURSE; DNA REPAIR; FEMALE; GENETICS; GENOTYPE; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MOLECULAR WEIGHT; PATHOLOGY; RECTUM TUMOR; TUMOR SUPPRESSOR GENE;

CD82 ANTIGEN; KAI1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; ONCOPROTEIN; TUMOR PROTEIN;

ADENOMA; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIGENS, CD; CARCINOMA; CELL ADHESION; COLON; COLONIC NEOPLASMS; DISEASE PROGRESSION; DNA REPAIR; DOWN-REGULATION; FEMALE; GENES, P53; GENOTYPE; HUMANS; KANGAI-1 PROTEIN; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MOLECULAR WEIGHT; NEOPLASM PROTEINS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; RECTAL NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033570375     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Ries, L. A. G., Kosary, C. L., Hankey, B. F., Miller, B. A., and Edwards, B. K. SEER Cancer Statistics Review, 1973-1996. Bethesda, MD: National Cancer Institute, 1999.
2. Landis, S., Murray, T., and Bolden, S. Cancer statistics. CA Cancer J. Clin., 49: 8-31, 1999.
3. Kinzler, K. W., and Vogelstein, B. Colorectal tumors. In: B. Vogelstein and K. W. Kinzler (eds.), The Genetic Basis of Human Cancer, Ed. 1, pp. 565-87. New York: McGraw-Hill, 1998.
4. Dale, D. C., and Federman, D. D. Scientific American medicine. In: R. J. Mayer (ed.), Gastrointestinal Cancer, pp. 14. New York: Scientific American, Inc., 1996.
5. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer [see comments], Lancet, 345: 939-944, 1995.
6. Hartsough, M. T., and Steeg, P. S. Nm23-H1: genetic alterations and expression patterns in tumor metastasis. Am. J. Hum. Genet., 63: 6-10, 1998.
7. van der Wurff, A. A., Arends, J. W., van der Linden, E. P., ten Kate, J., and Bosman, F. T. L-CAM expression in lymph node and liver metastases of colorectal carcinomas. J. Pathol., 172: 177-181, 1994.
8. Dorudi, S., Hanby, A. M., Poulsom, R., Northover, J., and Hart, I. R. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br. J. Cancer, 71: 614-616, 1995.
9. Tanabe, K. K., Ellis, L. M., and Saya, H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet, 341: 725-726, 1993.
10. Mulder, J. W., Kruyt, P. M., Sewnath, M., Oosting, J., Seldenrijk, C. A., Weidema, W. F., Offerhaus, G. J., and Pals, S. T. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins [see comments]. Lancet, 344: 1470-1472, 1994.
11. Tannapfel A., Kockerling, F., Katalinic, A., and Wittekind, C. Expression of nm23-H1 predicts lymph node involvement in colorectal carcinoma [published erratum appears in Dis. Colon Rectum 38: 802, 1995]. Dis Colon Rectum, 38: 651-654, 1995.
12. Haut, M., Steeg, P. S., Willson, J. K., and Markowitz, S. D. Induction of nm23 gene expression in human colonie neoplasms and equal expression in colon tumors of high and low metastatic potential. J. Natl. Cancer Inst., 83: 712-716, 1991.
13. Heys, S. D., Langlois, N., Smith, I. C., Walker, L. G., and Eremin, O. NM23 gene product expression does not predict lymph node metastases or survival in young patients with colorectal cancer. Oncol. Rep., 5: 735-739, 1998.
14. Yamaguchi, A., Urano, T., Fushida, S., Furukawa, K., Nishimura, G., Yonemura, Y., Miyazaki, I., Nakagawara, G., and Shiku, H. Inverse association of nm23-H1 expression by colorectal cancer with liver metastasis. Br. J. Cancer, 68: 1020-1024, 1993.
15. Cheah, P. Y., Cao, X., Eu, K. W., and Seow-Choen, F. NM23-H1 immunostaining is inversely associated with tumour staging but not overall survival or disease recurrence in colorectal carcinomas. Br. J. Cancer, 77: 1164-1168, 1998.
16. Dong, J. T., Lamb, P. W., Rinker-Schaeffer, C. W., Vukanovic, J., Ichikawa, T., Isaacs, J. T., and Barrett, J. C. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2 [see comments]. Science (Washington DC), 268: 884-886, 1995.
17. Ramshaw, I. A., Carlsen, S., Wang, H. C., and Badenoch-Jones, P. The use of cell fusion to analyse factors involved in tumour cell metastasis. Int. J. Cancer, 32: 471-478, 1983.
18. Sidebottom, E., and Clark, S. R. Cell fusion segregates progressive growth from metastasis. Br. J. Cancer, 47: 399-405, 1983.
19. Ichikawa, T., Ichikawa, Y., Dong, J., Hawkins, A. L., Griffin, C. A., Isaacs, W. B., Oshimura, M., Barrett, J. C., and Isaacs, J. T. Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res., 52: 3486-3490, 1992.
20. Maecker, H. T., Todd, S. C., and Levy, S. The tetraspanin superfamily: molecular facilitators. FASEB J., 11: 428-442, 1997.
21. Ikeyama, S., Koyama, M., Yamaoko, M., Sasada, R., and Miyake, M. Suppression of cell motilily and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J. Exp. Med., 177: 1231-1237, 1993.
22. Kondoh, M., Ueda, M., Ichihashi, M., and Mishima, Y. Decreased expression of human melanoma-associated antigen ME491 along the progression of melanoma pre-canceroses to invasive and metastatic melanomas. Melanoma Res., 3: 241-245, 1993.
23. Huang, C. L., Taki, T., Adachi, M., Yagita, M., Sawada, S., Takabayashi, A., Inufusa, H., Yoshie, O., and Miyake, M. MRP-1/CD9 and KAI1/CD82 expression in normal and various career tissues. Int. J. Oncol., 11: 1045-1051, 1997.
24. White, A., Lamb, P. W., and Barrett, J. C. Frequent downregulation of the KAI1(CD82) metastasis suppressor protein in human cancer cell lines. Oncogene, 16: 3143-3149, 1998.
25. Mannion, B. A., Berditchevski, F., Kraeft, S. K., Chen, L. B., and Hemler, M. E. Transmembrane-4 superfamily proteins CD81 (TAPA-1), CD82, CD63, and CD53 specifically associated with integrin α4β1 (CD49d/CD29). J. Immunol., 157: 2039-2047, 1996.
26. Rubinstein, E., Le Naour, F., Lagaudriere-Gesbert, C., Billard, M., Conjeaud, H., and Boucheix, C. CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur J. Immunol., 26: 2657-2665, 1996.
27. Afshari, C., Bruno, M., Lamb, P., Kenney, N., and Barrett, J. C. Interaction of the metastasis suppressing proteins KAI1 and E-cadherin in epithelial cells. Proc. Am. Assoc. Cancer Res., 40: 197, 1999.
28. Takaoka, A., Hinoda, Y., Satoh, S., Adachi, Y., Itoh, F., Adachi, M., and Imai, K. Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene. Oncogene, 16: 1443-1453, 1998.
29. Fukudome, K., Furuse, M., Imai, T., Nishimura, M., Takagi, S., Hinuma, Y., and Yoshie, O. Identification of membrane antigen C33 recognized by monoclonal antibodies inhibitory to human T-cell leukemia virus type 1 (HTLV-1)-induced syncytium formation: altered glycosylation of C33 antigen in HTLV-1-positive T cells. J. Virol., 66: 1394-1401, 1992.
30. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
31. Neufeld, K. L., and White, R. L. Nuclear and cytoplasmic localizations of the adenomatous polyposis coli protein. Proc. Natl. Acad. Sci. USA, 94: 3034-3039, 1997.
32. Morin, P. J., Vogelstein, B., and Kinzler, K. W. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA, 93: 7950-7954, 1996.
33. Hargest, R., and Williamson, R. Expression of the APC gene after transfection into a colonic cancer cell line. Gut, 37: 826-829, 1995.
34. Ilyas, M., Tomlinson, I. P., Rowan, A., Pignatelli, M., and Bodmer, W. F. β-Catenin mutations in cell lines established from human colorectal cancers. Proc. Natl. Acad. Sci. USA, 94: 10330-10334, 1997.
35. Cottrell, S., Bicknell, D., Kaklamanis, L., and Bodmer, W. F. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas [see comments]. Lancet, 340: 626-630, 1992.
36. Lengauer, C., Kinzler, K. W., and Vogelstein, B. Genetic instability in colorectal cancers. Nature (Lond.), 386: 623-627, 1997.
37. Groden, J., Joslyn, G., Samowitz, W., Jones, D., Bhattacharyya, N., Spirio, L., Thliveris, A., Robertson, M., Egan, S., Meuth, M., et al. Response of colon cancer cell lines to the introduction of APC, a colon-specific tumor suppressor gene. Cancer Res., 55: 1531-1539, 1995.
38. Mashimo, T., Watabe, M., Hirota, S., Hosobe, S., Miura, K., Tegtmeyer, P. J., Rinker-Shaeffer, C. W., and Watabe, K. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc. Natl. Acad. Sci. USA, 95: 11307-11311, 1998.
39. Rodrigues, N. R., Rowan, A., Smith, M. E., Kerr, I. B., Bodmer, W. F., Gannon, J. V., and Lane, D. P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA, 87: 7555-7559, 1990.
40. Li, C. Y., Suardet, L., and Little, J. B. Potential role of WAF1/Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. J. Biol. Chem., 270: 4971-4974, 1995.
41. Varesco, L., Groden, J., Spirio, L., Robertson, M., Weiss, R., Gismondi, V., Ferrara, G. B., and White, R. A rapid screening method to detect nonsense and frameshift mutations: identification of disease-causing APC alleles. Cancer Res., 53: 5581-5584, 1993.
42. Aquilina, G., Ceccotti, S., Martinelli, S., Hampson, R., and Bignami, M. N-(2-Chloroethyl)-N′-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells. Cancer Res., 58: 135-141, 1998.
43. Shibata, D., Peinado, M. A., Ionov, Y., Malkhosyan, S., and Perucho, M. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat. Genet., 6: 273-281, 1994.
44. Liu, B., Nicolaides, N. C., Markowitz, S., Willson, J. K., Parsons, R. E., Jen, J., Papadopolous, N., Peltomaki, P., de la Chapelle, A., Hamilton, S. R., Kinzler, K. W., and Vogelstein, B. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat. Genet., 9: 48-55, 1995.
45. Umar, A., Boyer, J. C., Thomas, D. C., Nguyen, D. C., Risinger, J. I., Boyd, J., Ionov, Y., Perucho, M., and Kunkel, T. A. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J. Biol. Chem., 269: 14367-14370, 1994.
46. Gil, M. L., Vita, N., Lebel-Binay, S., Miloux, B., Chalon, P., Kaghad, M., Marchiol-Fournigault, C., Conjeaud, H., Caput, D., Ferrara, P., Fradelizi, D., and Quillet-Mary, A. A member of the tetra spans transmembrane protein superfamily is recognized by a monoclonal antibody raised against an HLA class I-deficient, lymphokine-activated killer-susceptible, B lymphocyte line. Cloning and preliminary functional studies. J. Immunol., 148: 2826-2833, 1992.
47. Imai, T., Fukudome, K., Takagi, S., Nagira, M., Furuse, M., Fukuhara, N., Nishimura, M., Hinuma, Y., and Yoshie, O. C33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63. J. Immunol., 149: 2879-2886, 1992.
48. Higashiyama, M., Kodama, K., Yokouchi, H., Takami, K., Adachi, M., Taki, T., Ishiguro, S., Nakamori, S., Yoshie, O., and Miyake, M. KAI1/CD82 expression in non-small cell lung carcinoma is a novel, favorable prognostic factor: an immunohistochemical analysis. Cancer (Phila.), 83: 466-474, 1998.
49. Dong, J. T., Suzuki, H., Pin, S. S., Bova, G. S., Schalken, J. A., Isaacs, W. B., Barrett, J. C., and Isaacs, J. T. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res., 56: 4387-4390, 1996.
50. Huang, C. I., Kohno, N., Ogawa, E., Adachi, M., Taki, T., and Miyake, M. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am. J. Pathol., 153: 973-983, 1998.
51. Uchida, S., Shimada, Y., Watanabe, G., Li, Z. G., Hong, T., Miyake, M., and Imamura, M. Molility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br. J. Cancer, 79: 1168-1173, 1999.
52. Hinoda, Y., Adachi, Y., Takaoka, A., Mitsuuchi, H., Satoh, Y., Itoh, F., Kondoh, Y., and Imai, K. Decreased expression of the metastasis suppressor gene KAI1 in gastric cancer. Cancer Lett., 129: 229-234, 1998.
53. Guo, X. Z., Friess, H., Di Mola, F. F., Heinicke, J. M., Abou-Shady, M., Graber, H. U., Baer, H. U., Zimmermann, A., Korc, M., and Buchler, M. W. KAI1, a new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma. Hepatology, 28: 1481-1488, 1998.
54. Friess, H., Guo, X. Z., Berberat, P., Graber, H. U., Zimmermann, A., Korc, M., and Buchler, M. W. Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases. Int. J. Cancer, 79: 349-355, 1998.
55. Yu, Y., Yang, J. L., Markovic, E., Jackson, P., Yardley, G., Barrett, J., and Russell, P. J. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clin. Cancer Res., 3: 1045-1049, 1997.
56. Sho, M., Adachi, M., Taki, T., Hashida, H., Konishi, T., Huang, C. L., Ikeda, N., Nakajima, Y., Kanehiro, H., Hisanaga, M., Nakano, H., and Miyake, M. Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int. J. Cancer, 79: 509-516, 1998.
57. Hao, X., Palazzo, J. P., Ilyas, M., Tomlinson, I., and Talbot, I. C. Reduced expression of molecules of the cadherin/catenin complex in the transition from colorectal adenoma to carcinoma. Anticancer Res., 17: 2241-2247, 1997.
58. Geradts, J., Maynard, R., Birrer, M. J., Hendricks, D., Abbondanzo, S. L., Fong, K. M., Barrett, J. C., and Lombardi, D. P. Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues. Am. J. Pathol., 154: 1665-1671, 1999.
59. Dennis, J. W. Changes in glycosylation associated with malignant transformation and tumor progression. In: M. Fukuda (ed.), Cell Surface Carbohydrates and Cell Development, pp. 161-194. Boca Raton, FL: CRC Press, 1992.
60. Seelentag, W. K., Li, W. P., Schmitz, S. F., Metzger, U., Aeberhard, P., Heitz, P. U., and Roth, J. Prognostic value of β1,6-branched oligosaccharides in human colorectal carcinoma. Cancer Res., 58: 5559-5564, 1998.
61. Ono, M., Handa, K., Withers, D. A., and Hakomori, S. Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation. Cancer Res., 59: 2335-2339, 1999.